Comprehensive Lentiviral Vector (LV) Testing Solutions
Lentiviral vectors remain the backbone of many CAR-T, TCR, and ex vivo gene-modified cell therapies. Accelevir’s LV vector copy number assays, integration site analysis, and residual lentivirus detection workflows help developers meet GLP LV testing and regulatory submission standards.
Challenges in Lentiviral Vector Development
- Vector copy number (VCN): Determining CAR or transgene copies per genome in modified cells.
- Integration site mapping: Assessing insertion patterns for safety.
- Residual vector detection: Ensuring absence of replication-competent lentivirus (RCL).
- Cellular phenotyping: Monitoring CAR+ T cell persistence and activation/exhaustion status.
- Cytokine release risk: Detecting CRS potential preclinically and clinically.
How Accelevir Supports LV Programs
- Vector Copy Number Analysis
- Multiplex dPCR/qPCR for accurate VCN quantification in manufacturing and patient samples.
- Integration Site Analysis
- Targeted NGS to identify insertion loci and assess clonal expansion risk.
- Residual Vector Detection
- Ultra-sensitive assays for RCL in cell product and patient follow-up samples.
- Immune Monitoring of Transduced Cells
- Flow cytometry for CAR+ cell phenotype, activation markers, and memory subsets.
- Cytolytic assays to confirm functional potency.
- Cytokine Release Profiling
- Multiplex Luminex and ELISA panels to detect inflammatory cytokines linked to CRS.
Why Partner with Accelevir
- Deep expertise in vector analytics for regulated submissions.
- Integrated cellular and molecular readouts.
- CLIA-certified and GLP-capable workflows.
- BSL-2+ facilities for safe handling of viral vectors and patient samples.